V-Sampler standardizes the process of preparing blood smears of high quality. The instrument enables simultaneous preparation of 2 smears and allows the setting of thickness and size of the smear. Compact and lightweight, the instrument is simple and easy to use.

Read more

The Alere i Influenza A & B test is the first and only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. The test is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy and the UK.  Molecular testing involves the extraction and analysis of DNA or RNA strands to detect sequences associated with viral and bacterial causes of infections.  Alere i Influenza A & B is the first molecular diagnostic test that delivers actionable, lab-accurate results in less than 15 minutes on a user-friendly platform.  The proprietary technology utilizes isothermal nucleic acid amplification technology (iNAT), which, unlike polymerase chain reaction (PCR) testing, does not require temperature cycling and can therefore deliver results more quickly and to a broader range of settings, including point of care as well as laboratory.  Each year, a combination of influenza A and B virus strains circulate within Europe. Up to 40,000 people die each year from influenza in the EU, according to the European Centre for Disease Prevention and Control (ECDC). The disease also poses a significant economic burden including medical care expenses and loss of productivity. Rapid diagnostics with increased sensitivity are essential for the reliable detection of influenza A and B, enabling healthcare professionals to make immediate, effective treatment decisions and prevent unnecessary prescribing of antibiotics and antiviral medications. Rapid diagnosis of influenza can help reduce length of hospital stays, secondary complications and the cost of hospital care, and allow effective implementation of infection control measures.
Read more

Designed for in vitro professional and self-testing, the Mission Cholesterol Monitoring System includes individual test devices and a 3-1 lipid panel test device which tests for Total Cholesterol (CHOL), High Density Lipoprotein (HDL), Triglycerides (TRIG), and also calculates Low Density Lipoprotein (LDL), CHOL/HDL ratio, and Cardiac Risk Assessment. Results are provided in as little as 45 seconds with a required specimen size of 35 µL. Other features include a large LCD display for easy reading and 200 test memory with Date/Time. The system is CE-marked for professional and OTC sales in Europe and other international markets. It is well suited for use in physician offices, homes, community health centres, hospitals, public and private labs, and pharmacies. Patients and home users will be able to better monitor their cholesterol levels in order to reduce the risk of heart disease, strokes, and heart attacks.

Read more

The Aptima HIV-1 Quant Dx assay has now been introduced on the Panther system, allowing complete sample-to-result automation in the only in vitro nucleic acid amplification test (NAAT) for both the detection and quantitation of HIV-1 RNA. The Aptima HIV-1 Quant Dx assay is intended for use as an aid in both the diagnosis and confirmation of HIV-1 infection as well as in the clinical management of patients infected with HIV-1. This highly sensitive assay can detect HIV-1 RNA as low as 13 copies/mL using a 0.5 mL sample.  The Aptima HIV-1 Quant Dx assay offers the advantage of having a limit of detection (LOD) that is not equal to the lower limit of quantitation (LLOQ) when utilized for diagnosis, to enable the assay to detect HIV-1 viral load below quantifiable levels. The assay’s broad dynamic range allows quantification of HIV-1 RNA, from 30 copies/mL to 10 million copies/mL. High precision in quantitation is ensured, with a narrow coefficient of variation across the linear range—including in low-viremia samples. The Aptima HIV-1 Quant Dx assay provides 3 levels of protection for confidence in assay performance despite drug selection pressures and growing genetic diversity.  This is achieved by the use of a dual-target approach for built-in redundancy, with both targets chosen within highly conserved genomic regions (LTR and pol) of HIV-1 together with a sophisticated primer design – including length – to tolerate mutations; as well as redundant oligonucleotides for additional protection against mutations. The random access Panther system eliminates batching restrictions and allows the user to run HIV-1 side by side with 3 other sexually transmitted disease/sexually transmitted infection (STD/STI) testing assays: CT/NG, HPV and Trichomonas. Primary tubes can be loaded and processed directly with no aliquot or manual transfer to a second tube required.

Read more